MD Anderson Cancer Center spinout OncoResponse has added $40.6m to its coffers thanks to series C investors including Arch Venture Partners.

OncoResponse, a US-based immunotherapy spinout of University of Texas MD Anderson Cancer Center, picked up $40.6m in a series C round today led by members of asset manager Magnetar Group. Arch Venture Partners, Yonjin Venture, Bering Capital, RiverVest Venture Partners, Qatar Investment Authority (QIA), Redmile Group, Canaan Partners and 3B Future Health Fund (Helsinn Investment Fund), a vehicle for cancer drug developer Helsinn Group. OncoResponse is developing antibodies intended to harness the body’s immune system to combat specific cancer targets. The money will allow OncoResponse to advance its lead asset into clinical development for multiple tumour types and to fund preclinical development. Ted Koutouzis of Magnetar, Daguang Wang of Yonjin and Patrick Hojlo of QIA will join the board of directors. OncoResponse closed a $40m series B round featuring William Marsh Rice University in 2018. RiverVest Venture Partners led the round, which included Helsinn and Alexandria Venture Investments, a subsidiary of real estate investment trust Alexandria Real Estate Equities. Arch Venture Partners, HT Family Office, Canaan Partners, QIA and Redmile Group filled out the series B round. The spinout completed a $22.5m series A round in 2017 that included MD Anderson, William Marsh Rice University, Helsinn, Alexandria Real Estate Equities and Baxalta, the biopharmaceutical company subsequently acquired by pharmaceutical firm Shire. HT Family Office, GreatPoint Ventures, Arch Venture Partners and Canaan Partners also participated in the series A round.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).